Anzeige
Mehr »
Login
Freitag, 24.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40F75 | ISIN: FR001400Q9V2 | Ticker-Symbol: H8Y
Frankfurt
23.01.25
21:50 Uhr
21,200 Euro
+0,650
+3,16 %
Branche
Elektrotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
EXOSENS SA Chart 1 Jahr
5-Tage-Chart
EXOSENS SA 5-Tage-Chart
RealtimeGeldBriefZeit
21,20021,65023.01.
ACCESS Newswire
237 Leser
Artikel bewerten:
(1)

Exosens: Photonis Showcases Advanced Nuclear Instrumentation Solutions at Utility Working Conference

Finanznachrichten News

MARCO ISLAND, FL / ACCESSWIRE / July 30, 2024 / Photonis, part of Exosens, a leading global provider of neutron and gamma detectors for the nuclear industry, announces its participation at the American Nuclear Society's Utility Working Conference and Vendor Technology Expo from August 4-7, 2024, in Marco Island, Florida. This event marks Photonis' strategic initiative to expand its presence in the U.S. market, showcasing its commitment to delivering high-quality, customized solutions tailored to the unique needs of the nuclear industry.

Photonis at UWC

Photonis at UWC

With over 50 years of experience designing and manufacturing nuclear instrumentation for French nuclear power plants and research programs, Photonis brings a wealth of expertise to the American market. The company's comprehensive catalog of nuclear components includes market-leading technology such as High-Temperature In-Core and Ex-Core Fission Chambers, Miniature Gamma Ionization Chambers, and High-Sensitivity Boron-Lined Proportional Counters. Also featured are Mineral Insulated Cable Extensions and Connectors, highlighting Photonis' capability in product development and adaptation.

This extensive experience and innovative product range have earned Photonis a reputation as a trusted partner in the nuclear industry, with customers relying on its nuclear instrumentation in over 180 nuclear power plants worldwide. Additionally, Photonis is a critical component supplier for the French Alternative Energies and Atomic Energy Commission (CEA), further solidifying its reputation as a leading provider of high-quality nuclear detection solutions.

Photonis' neutron and gamma detectors play a crucial role in ensuring safety and control of nuclear reactors, fuel reprocessing plants, radioactive waste storage, and nuclear research facilities worldwide. By expanding its presence in the U.S. market, Photonis aims to establish itself as a trusted partner capable of delivering high-quality, tailored solutions that meet the evolving needs of industry stakeholders.

"We are thrilled to participate in the ANS Utility Working Conference and introduce our advanced nuclear instrumentation solutions to the U.S. market. Photonis is dedicated to meeting the stringent safety and regulatory requirements of the nuclear industry and to becoming one of the major solutions providers in the North American market. We look forward to engaging with U.S. customers and demonstrating how our technologies can enhance the safety and efficiency of their operations," said Ulrich Laupper, President and Executive General Manager of the Ultimate Detection Business Unit of Exosens.

The company's commitment to excellence is underscored by its dedicated Research and Development team, operating under ISO9001, ISO19443, RCCE (EDF Rules), ASME NQA-1, and HAF604 certifications, ensuring rigorous quality standards across all operations.

Attendees of the ANS Utility Working Conference are invited to visit Photonis at booth #105 to explore its wide range of innovative nuclear instrumentation solutions and discuss partnership opportunities.

ABOUT PHOTONIS:

Photonis is a leading product brand of Exosens, a high-tech company with more than 85 years of experience in the innovation, development, manufacture and sale of high-end electro-optical technologies. Photonis offers its customers photo-detection and low-light conditions imaging solutions for extremely demanding environments such as Defense & Security, Nuclear Safety, Life Science and Industrial & Non-Destructive testing. Photonis is internationally recognized as a leading brand and a major innovator in its fields with production and R&D sites in Europe and North America.

For more information: exosens.com.

Contact Information:

Sales Manager
Nuclear Instrumentation Sales Manager - North America
nuclearsales@exosens.com
508-744-8769

SOURCE: Photonis Scientific, Inc.

.

View the original press release on newswire.com.

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.